HIV-1 Infection - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 319 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

HIV-1 Infection - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘HIV-1 Infection - Pipeline Review, H1 2015’, provides an overview of the HIV-1 Infection’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of HIV-1 Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for HIV-1 Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the HIV-1 Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline"

 Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
HIV-1 Infection Overview 12
Therapeutics Development 13
Pipeline Products for HIV-1 Infection - Overview 13
Pipeline Products for HIV-1 Infection - Comparative Analysis 14
HIV-1 Infection - Therapeutics under Development by Companies 15
HIV-1 Infection - Therapeutics under Investigation by Universities/Institutes 19
HIV-1 Infection - Pipeline Products Glance 24
Late Stage Products 24
Clinical Stage Products 25
Early Stage Products 26
Unknown Stage Products 27
HIV-1 Infection - Products under Development by Companies 28
HIV-1 Infection - Products under Investigation by Universities/Institutes 33
HIV-1 Infection - Companies Involved in Therapeutics Development 38
AlphaVax, Inc. 38
AltraVax Inc. 39
Aphios Corporation 40
Argos Therapeutics, Inc. 41
Bionor Pharma ASA 42
Biosantech SA 43
Boehringer Ingelheim GmbH 44
Bristol-Myers Squibb Company 45
CompleGen, Inc. 46
Critical Outcome Technologies Inc. 47
CytoDyn Inc. 48
Enzo Biochem, Inc. 49
FIT Biotech Oy 50
GeneCure LLC 51
Gilead Sciences, Inc. 52
GlaxoSmithKline plc 53
Heat Biologics, Inc. 54
InnaVirVax SA 55
Inovio Pharmaceuticals, Inc. 56
Johnson & Johnson 57
Merck & Co., Inc. 58
Mymetics Corporation 59
Myrexis, Inc. 60
Oncovir, Inc. 61
OyaGen Inc. 62
Peregrine Pharmaceuticals, Inc. 63
Pfizer Inc. 64
Pharis Biotec GmbH 65
Spider Biotech 66
TaiMed Biologics Inc. 67
Takara Bio Inc. 68
Theravectys S.A. 69
Tobira Therapeutics, Inc. 70
United Biomedical, Inc. 71
Valens Therapeutics, Inc. 72
Vichem Chemie Research Ltd. 73
ViiV Healthcare Limited 74
HIV-1 Infection - Therapeutics Assessment 75
Assessment by Monotherapy Products 75
Assessment by Combination Products 76
Assessment by Target 77
Assessment by Mechanism of Action 80
Assessment by Route of Administration 83
Assessment by Molecule Type 85
Drug Profiles 87
(cenicriviroc mesylate + lamivudine + efavirenz) - Drug Profile 87
(cenicriviroc mesylate + lamivudine) - Drug Profile 88
(darunavir + cobicistat + emtricitabine + tenofovir alafenamide) - Drug Profile 89
(dolutegravir + rilpivirine) - Drug Profile 91
(elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide) - Drug Profile 92
(emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide) - Drug Profile 94
(emtricitabine + tenofovir alafenamide) - Drug Profile 95
(lamivudine + raltegravir potassium) - Drug Profile 96
1-E703 - Drug Profile 97
3B3-PE38 - Drug Profile 98
AGS-004 - Drug Profile 99
AH-0109 - Drug Profile 101
ALVAC-HIV vCP1521 + AIDSVAX B/B - Drug Profile 102
Antibodies to Inhibit gp120 for HIV-1 Infection - Drug Profile 104
Antisense Oligonucleotides to Inhibit GAG for HIV-1 Infection - Drug Profile 105
APH-0812 - Drug Profile 106
AVX-101 - Drug Profile 107
BMS-585248 - Drug Profile 108
BMS-955176 - Drug Profile 109
CCL-14 - Drug Profile 110
Cell Therapy for HIV-1 Infection - Drug Profile 111
censavudine - Drug Profile 112
CG-1 - Drug Profile 114
CGX-0471 - Drug Profile 115
CGX-1079 - Drug Profile 116
CPI-43132 - Drug Profile 117
Dendritic Cell Therapy for HIV-1 Infection - Drug Profile 118
doravirine - Drug Profile 119
Drug to Inhibit Reverse Transcriptase for HIV-1 - Drug Profile 120
Drugs to Antagonize P2X for HIV-1 Infection - Drug Profile 121
Drugs to Inhibit HIV-1 Protease for HIV-1 Infection - Drug Profile 122
Drugs to Inhibit Reverse Transcriptase for Viral Infections - Drug Profile 123
Drugs to Inhibit Vif Protein for HIV-1 Infection - Drug Profile 124
DS-001 - Drug Profile 125
DS-003 - Drug Profile 126
DS-007 - Drug Profile 127
F2 - Drug Profile 128
FIT-06 + LIPO-5 - Drug Profile 129
fostemsavir - Drug Profile 130
FP-1 - Drug Profile 132
Gene Therapy for HIV-1 Infection - Drug Profile 133
Gene Therapy to Activate MazF Gene for HIV-1 - Drug Profile 134
Gene Therapy to Inhibit Gag for HIV-1 Infection - Drug Profile 136
GRL-0519 - Drug Profile 137
GS-8374 - Drug Profile 138
GS-9883 - Drug Profile 139
GSK-732462 - Drug Profile 140
HGTV-43 - Drug Profile 141
HIV [serotype 5] vaccine - Drug Profile 142
HIV [type 1] vaccine - Drug Profile 144
HIV Vaccine - Drug Profile 146
HIV vaccine - Drug Profile 147
HIV vaccine - Drug Profile 148
HIV-1 vaccine - Drug Profile 149
HIV-1 vaccine - Drug Profile 150
HIV-1 vaccine - Drug Profile 151
HIV-1 vaccine - Drug Profile 152
HIV-1 vaccine - Drug Profile 153
HIV-1 vaccine - Drug Profile 154
HIV-1 vaccine - Drug Profile 155
HIV-1 vaccine - Drug Profile 156
HIV-1 vaccine - Drug Profile 157
HIV-1 vaccine - Drug Profile 158
HIV-1 vaccine (bivalent) - Drug Profile 159
HIV-1 vaccine 1 - Drug Profile 160
HIV-1 vaccine 1 - Drug Profile 161
HIV-1 vaccine 3 - Drug Profile 162
HIV-1 vaccine 4 - Drug Profile 164
HIV-1 vaccine 5 - Drug Profile 165
HIVAX - Drug Profile 167
HNG-156 - Drug Profile 168
HS-HIV1 - Drug Profile 169
HUM-8P.342 - Drug Profile 170
ibalizumab - Drug Profile 171
Leukothera - Drug Profile 173
M-48U1 - Drug Profile 174
MK-8507 - Drug Profile 175
MK-8591 - Drug Profile 176
MK-8970 - Drug Profile 177
MYMV-101 - Drug Profile 178
MYMV-201 - Drug Profile 180
NB-325 - Drug Profile 181
PENNVAX-B - Drug Profile 183
Peptides to Target TAR for HIV-1 Infection - Drug Profile 185
PF-46396 - Drug Profile 186
PGN-632 - Drug Profile 187
Poly-ICLC - Drug Profile 188
PRO-140 - Drug Profile 190
Protein for HIV-1 Infection - Drug Profile 192
Protein to Inhibit Tat and Rev for HIV-1 - Drug Profile 193
rAd5 Env A + rAd35 Env A Vaccine - Drug Profile 194
RC-100b - Drug Profile 195
Recombinant Enzyme for HIV-1 Infection - Drug Profile 196
Recombinant Peptide to Inhibit gp120 for HIV-1 - Drug Profile 197
Recombinant Peptides for HIV-1 Infection and Influenza A Infections - Drug Profile 198
Recombinant Protein to Target gp120 for HIV-1 Infection - Drug Profile 199
Recombinant Protein to Target gp120 for HIV-1 Infections - Drug Profile 200
rilpivirine - Drug Profile 201
RN-18 - Drug Profile 203
SB-105A10 - Drug Profile 204
Small Molecule for HIV-1 Infection - Drug Profile 206
Small Molecule for HIV-1 Infection - Drug Profile 207
Small Molecule to Inhibit Gag for HIV-1 Infection - Drug Profile 208
Small Molecule to Inhibit HIV-1 Protease for HIV-1 Infection - Drug Profile 209
Small Molecule to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection - Drug Profile 210
Small Molecule to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection - Drug Profile 211
Small Molecule to Inhibit Reverse Transcriptase for HIV-1 infection - Drug Profile 212
Small Molecule to Target Capsid Protein for HIV-1 Infection - Drug Profile 213
Small Molecule to Target Matrix Protein for HIV-1 Infection - Drug Profile 214
Small Molecules for HIV-1 Infection - Drug Profile 215
Small Molecules for HIV-1 Infection - Drug Profile 216
Small Molecules for HIV-1 Infection - Drug Profile 217
Small Molecules for HIV-1 Infection - Drug Profile 218
Small Molecules for HIV-1 Infection - Drug Profile 219
Small Molecules for HIV-1 Infections - Drug Profile 220
Small Molecules for HIV-1, Neurodegenerative Disorders and Type 2 Diabetes - Drug Profile 221
Small Molecules for Retroviral Infections - Drug Profile 222
Small Molecules to Inhibit CDK9 for HIV-1 Infection - Drug Profile 223
Small Molecules to Inhibit Glycoprotein and HIV Integrase for HIV-1 Infection - Drug Profile 224
Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection - Drug Profile 225
Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 - Drug Profile 227
Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection - Drug Profile 228
Small Molecules to Inhibit HIV-1 RT for HIV-1 Infection - Drug Profile 229
Small Molecules to Inhibit Nef for HIV-1 Infections - Drug Profile 230
Small Molecules to Inhibit Nuclear Export for Viral Infections and Cancer - Drug Profile 231
Small Molecules to Inhibit p25 and gp120 for HIV-1 Infection - Drug Profile 232
Small Molecules to Inhibit Ribonuclease H for HIV-1 Infection - Drug Profile 233
Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile 234
Stem Cell Therapy for HIV-1 Infection and Melanoma - Drug Profile 235
SV6-B - Drug Profile 236
SV6-C - Drug Profile 237
SVC-2 - Drug Profile 238
SVH1-C - Drug Profile 239
SVH1-D - Drug Profile 240
Synthetic Peptide 2 for HIV-1 Infection - Drug Profile 241
Synthetic Peptide for HIV-1 Infection - Drug Profile 242
Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 243
THV-01 - Drug Profile 244
TMC-310911 - Drug Profile 246
UB-421 - Drug Profile 247
VAC-3S - Drug Profile 248
Vacc-4x - Drug Profile 250
Vacc-C5 - Drug Profile 254
VIR-353 - Drug Profile 256
VIR-576 - Drug Profile 257
VRC-01 - Drug Profile 258
VRC-02 - Drug Profile 260
HIV-1 Infection - Recent Pipeline Updates 261
HIV-1 Infection - Dormant Projects 286
HIV-1 Infection - Discontinued Products 296
HIV-1 Infection - Product Development Milestones 298
Featured News & Press Releases 298
Appendix 308
Methodology 308
Coverage 308
Secondary Research 308
Primary Research 308
Expert Panel Validation 308
Contact Us 308
Disclaimer 309

List of Tables

Number of Products under Development for HIV-1 Infection, H1 2015 23
Number of Products under Development for HIV-1 Infection - Comparative Analysis, H1 2015 24
Number of Products under Development by Companies, H1 2015 26
Number of Products under Development by Companies, H1 2015 (Contd..1) 27
Number of Products under Development by Companies, H1 2015 (Contd..2) 28
Number of Products under Investigation by Universities/Institutes, H1 2015 30
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 31
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 32
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 33
Comparative Analysis by Late Stage Development, H1 2015 34
Comparative Analysis by Clinical Stage Development, H1 2015 35
Comparative Analysis by Early Stage Development, H1 2015 36
Comparative Analysis by Unknown Stage Development, H1 2015 37
Products under Development by Companies, H1 2015 38
Products under Development by Companies, H1 2015 (Contd..1) 39
Products under Development by Companies, H1 2015 (Contd..2) 40
Products under Development by Companies, H1 2015 (Contd..3) 41
Products under Development by Companies, H1 2015 (Contd..4) 42
Products under Investigation by Universities/Institutes, H1 2015 43
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 44
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 45
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 46
Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 47
HIV-1 Infection - Pipeline by AlphaVax, Inc., H1 2015 48
HIV-1 Infection - Pipeline by AltraVax Inc., H1 2015 49
HIV-1 Infection - Pipeline by Aphios Corporation, H1 2015 50
HIV-1 Infection - Pipeline by Argos Therapeutics, Inc., H1 2015 51
HIV-1 Infection - Pipeline by Bionor Pharma ASA, H1 2015 52
HIV-1 Infection - Pipeline by Biosantech SA, H1 2015 53
HIV-1 Infection - Pipeline by Boehringer Ingelheim GmbH, H1 2015 54
HIV-1 Infection - Pipeline by Bristol-Myers Squibb Company, H1 2015 55
HIV-1 Infection - Pipeline by CompleGen, Inc., H1 2015 56
HIV-1 Infection - Pipeline by Critical Outcome Technologies Inc., H1 2015 57
HIV-1 Infection - Pipeline by CytoDyn Inc., H1 2015 58
HIV-1 Infection - Pipeline by Enzo Biochem, Inc., H1 2015 59
HIV-1 Infection - Pipeline by FIT Biotech Oy, H1 2015 60
HIV-1 Infection - Pipeline by GeneCure LLC, H1 2015 61
HIV-1 Infection - Pipeline by Gilead Sciences, Inc., H1 2015 62
HIV-1 Infection - Pipeline by GlaxoSmithKline plc, H1 2015 63
HIV-1 Infection - Pipeline by Heat Biologics, Inc., H1 2015 64
HIV-1 Infection - Pipeline by InnaVirVax SA, H1 2015 65
HIV-1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 66
HIV-1 Infection - Pipeline by Johnson & Johnson, H1 2015 67
HIV-1 Infection - Pipeline by Merck & Co., Inc., H1 2015 68
HIV-1 Infection - Pipeline by Mymetics Corporation, H1 2015 69
HIV-1 Infection - Pipeline by Myrexis, Inc., H1 2015 70
HIV-1 Infection - Pipeline by Oncovir, Inc., H1 2015 71
HIV-1 Infection - Pipeline by OyaGen Inc., H1 2015 72
HIV-1 Infection - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 73
HIV-1 Infection - Pipeline by Pfizer Inc., H1 2015 74
HIV-1 Infection - Pipeline by Pharis Biotec GmbH, H1 2015 75
HIV-1 Infection - Pipeline by Spider Biotech, H1 2015 76
HIV-1 Infection - Pipeline by TaiMed Biologics Inc., H1 2015 77
HIV-1 Infection - Pipeline by Takara Bio Inc., H1 2015 78
HIV-1 Infection - Pipeline by Theravectys S.A., H1 2015 79
HIV-1 Infection - Pipeline by Tobira Therapeutics, Inc., H1 2015 80
HIV-1 Infection - Pipeline by United Biomedical, Inc., H1 2015 81
HIV-1 Infection - Pipeline by Valens Therapeutics, Inc., H1 2015 82
HIV-1 Infection - Pipeline by Vichem Chemie Research Ltd., H1 2015 83
HIV-1 Infection - Pipeline by ViiV Healthcare Limited, H1 2015 84
Assessment by Monotherapy Products, H1 2015 85
Assessment by Combination Products, H1 2015 86
Number of Products by Stage and Target, H1 2015 88
Number of Products by Stage and Mechanism of Action, H1 2015 91
Number of Products by Stage and Route of Administration, H1 2015 94
Number of Products by Stage and Molecule Type, H1 2015 96
HIV-1 Infection Therapeutics - Recent Pipeline Updates, H1 2015 271
HIV-1 Infection - Dormant Projects, H1 2015 296
HIV-1 Infection - Dormant Projects (Contd..1), H1 2015 297
HIV-1 Infection - Dormant Projects (Contd..2), H1 2015 298
HIV-1 Infection - Dormant Projects (Contd..3), H1 2015 299
HIV-1 Infection - Dormant Projects (Contd..4), H1 2015 300
HIV-1 Infection - Dormant Projects (Contd..5), H1 2015 301
HIV-1 Infection - Dormant Projects (Contd..6), H1 2015 302
HIV-1 Infection - Dormant Projects (Contd..7), H1 2015 303
HIV-1 Infection - Dormant Projects (Contd..8), H1 2015 304
HIV-1 Infection - Dormant Projects (Contd..9), H1 2015 305
HIV-1 Infection - Discontinued Products, H1 2015 306
HIV-1 Infection - Discontinued Products (Contd..1), H1 2015 307